SRTS - Sensus Healthcare, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.85
+0.20 (+3.54%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.65
Open5.57
Bid5.31 x 800
Ask7.45 x 1000
Day's Range5.55 - 5.87
52 Week Range5.00 - 8.88
Volume18,641
Avg. Volume97,929
Market Cap94.1M
Beta (3Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.54
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Report: Exploring Fundamental Drivers Behind Affimed N.V, Sensus Healthcare, Lifetime Brands, SigmaTron International, Salem Media Group, and Origin Agritech — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of SRTS earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q3 2018 Sensus Healthcare Inc Earnings Call

  • PR Newswire17 days ago

    Sensus Healthcare Third Quarter Financial Results Feature Revenue Growth of 32%

    Shipped 18 systems during the quarter including 15 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. , Nov. 1, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. ...

  • PR Newswire27 days ago

    Sensus Healthcare to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 1, 2018

    BOCA RATON, Fla. , Oct. 22, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS),   a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • PR Newswirelast month

    Sensus Healthcare Brings Groundbreaking SRT-100 Vision System to Israel's Largest Hospital for Skin Cancer and Keloid Treatment

    BOCA RATON, Fla., Oct. 17, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company has shipped  its third SRT-100 Vision™ system to Israel, with the newest unit located at the Sheba Medical Center in Tel HaShomer, near Tel Aviv. The other two previously installed units reside at the Ichilov Hospital in Tel Aviv and Beilinson Hospital / Rabin Medical Center in Petah Tikva.

  • PR Newswirelast month

    South Florida Business Journal Recognizes Sensus Healthcare's Chief Technology Officer at 2018 Technology Awards

    BOCA RATON, Fla., Oct. 16, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the South Florida Business Journal has recognized the Company's Chief Technology Officer, Kal Fishman, as a finalist at this year's Technology Awards. "For nearly a decade, Kal has played an incredibly instrumental role in Sensus Healthcare's overarching success, and his vast accomplishments continue to be recognized each year, both locally and globally," said Joe Sardano, CEO of Sensus Healthcare.

  • PR Newswire2 months ago

    Sensus Healthcare, Inc. Announces Underwriters' Exercise of Option

    BOCA RATON, Fla., Sept. 21, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it has issued an additional 330,882 shares of its common stock pursuant to the exercise in full of the underwriters' option received in connection with Sensus' recently completed public offering of its common stock. After giving effect to the full exercise of the option, Sensus sold an aggregate of 2,536,764 shares of its common stock at a price of $6.80 per share with total gross proceeds of approximately $17.25 million, before deducting underwriting discounts and commissions and other estimated offering expenses. B. Riley FBR acted as the lead underwriter and sole book-running manager for the offering.

  • What You Must Know About Sensus Healthcare Inc’s (NASDAQ:SRTS) Financial Strength
    Simply Wall St.2 months ago

    What You Must Know About Sensus Healthcare Inc’s (NASDAQ:SRTS) Financial Strength

    Sensus Healthcare Inc (NASDAQ:SRTS) is a small-cap stock with a market capitalization of US$107.1m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • Sensus Healthcare, Inc. Announces Closing of Public Offering of Common Stock
    PR Newswire2 months ago

    Sensus Healthcare, Inc. Announces Closing of Public Offering of Common Stock

    BOCA RATON, Fla., Sept. 17, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it completed a public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. The shares are listed on The Nasdaq Capital Market under the ticker symbol "SRTS."  Total proceeds to Sensus from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $15 million. Sensus has granted the underwriters a 30-day option to purchase up to an additional 330,882 shares at the public offering price, less underwriting discounts and commissions. B. Riley FBR acted as the lead underwriter and sole book-running manager for the offering.

  • Sensus Healthcare, Inc. Announces Pricing of Public Offering of Common Stock
    PR Newswire2 months ago

    Sensus Healthcare, Inc. Announces Pricing of Public Offering of Common Stock

    BOCA RATON, Fla., Sept. 13, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it has priced an underwritten public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. Sensus has granted a 30-day option to purchase up to an additional 330,882 shares pursuant to the underwriting agreement. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • PR Newswire2 months ago

    Sensus Healthcare, Inc. Announces Commencement of Public Offering of Common Stock

    BOCA RATON, Fla., Sept. 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it commenced a public offering of its common stock, par value $0.01 per share. In addition, Sensus intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The offering will be made only by means of a prospectus supplement and an accompanying prospectus filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission on Form S-3.

  • PR Newswire2 months ago

    Sensus Healthcare Presents at National Cancer Care Alliance Leadership Board and Practice Quarterly Meeting

    BOCA RATON, Fla., Sept. 7, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, participated at the National Cancer Care Alliance (NCCA) Leadership Board and Practice Quarterly Meeting, which took place Thursday, August 30 through Friday, August 31, 2018, in Chicago. "At this pivotal point in Sensus' acceleration as an international provider of solutions for non-invasive skin cancer treatment, it is an honor to address the NCCA at the invitation of founder and current chair of the board Dr. Barbara McAneny," Sardano said.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of SRTS earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 Sensus Healthcare Inc Earnings Call

  • PR Newswire3 months ago

    Sensus Healthcare to Participate in Two Upcoming Investor Conferences

    BOCA RATON, Fla. , Aug. 27, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. (Nasdaq: SRTS ), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • CNW Group3 months ago

    Sensus Healthcare CEO Joseph C. Sardano Joins BirchBioMed Inc. Board of Directors

    VANCOUVER , Aug. 13, 2018 /CNW/ - BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation, today announced the appointment of Joseph C. Sardano to its board of directors. A recognized leader in the healthcare industry, Mr. Sardano is Chairman of the Board, President and CEO of Sensus Healthcare, Inc. (SRTS), which specializes in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT). Mr. Sardano's appointment as BirchBioMed's first independent director is effective immediately.

  • PR Newswire4 months ago

    Sensus Healthcare Second Quarter Financial Results Feature Continued Strong Revenue Growth

    Ships 21 systems including 12 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. , Aug. 2, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. (Nasdaq: SRTS ), a ...

  • ACCESSWIRE4 months ago

    Sensus Healthcare, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Sensus Healthcare, Inc. (NASDAQ: SRTS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...

  • PR Newswire4 months ago

    Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radiation Therapy for Treating Non-Melanoma Skin Cancer and Keloids

    BOCA RATON, Fla., Aug. 2, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company has received 501(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new SRT-100+, the next-generation Superficial Radiation Therapy solution that adds several innovative features to Sensus' existing SRT-100 product. "We have integrated both clinical and patient feedback to bring to life exciting new elements with the SRT-100+—from live lesion and patient cameras for monitoring during treatment to best-in-class system enhancements for better patient setup and comfort," said Kal Fishman, Chief Technology Officer, Sensus Healthcare.

  • PR Newswire4 months ago

    Sensus Healthcare CEO Receives "Innovator of the Year" Award at The Aesthetic Show 2018

    BOCA RATON, Fla., July 31, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company's CEO, Joe Sardano, has been named non-physician, nonsurgical "Innovator of the Year" at the 2018 Aesthetic Awards, hosted by The Aesthetic Channel, a media resource for cosmetic doctors.

  • PR Newswire4 months ago

    Sensus Healthcare to Host Second Quarter 2018 Financial Results and Business Update Conference Call on August 2, 2018

    BOCA RATON, Fla. , July 24, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • PR Newswire4 months ago

    Sensus Healthcare Announces Strategic Agreement with SkinCure Oncology

    BOCA RATON, Fla., July 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced a strategic agreement focused on marketing the SRT-100 Vision™ with SkinCure Oncology, a leading turnkey provider of IGSRT solutions in the dermatology industry. SkinCure uses the same quality and safety features of leading cancer center models for the delivery of Sensus' most technically advanced and innovative device to date, the SRT-100 Vision, to dermatology practices.

  • PR Newswire4 months ago

    Sensus Healthcare and CellMark Medical Partner to Accelerate International Expansion and Growth for Innovative Oncology and Aesthetic Solutions

    "CellMark Medical was formed to create a pathway for domestically successful, innovative medical technologies to expand from their home markets into emerging geographic locations around the world," said Oliver Moorhouse, Head of the Americas, CellMark Medical. "As the preference is to focus on underserved clinical areas, such as skin cancer and keloids, we view Sensus Healthcare as a partner for life, and the opportunity to expedite and sustain this global growth is truly a privilege. The collaboration aims to facilitate timely access for patients all over the world to Sensus' extensive portfolio of aesthetic and dermatology solutions, including SRT and Sensus Laser Systems, as well as the Company's future oncology solutions.

  • PR Newswire5 months ago

    Sensus Healthcare to Join Russell Microcap® Index

    BOCA RATON, Fla. , June 25, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. (NASDAQ: SRTS) , a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • PR Newswire5 months ago

    Sensus Healthcare to Participate in Panel Discussion at the Cantor Fitzgerald Dermatology & Aesthetics Summit

    BOCA RATON, Fla. , June 12, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. (NASDAQ: SRTS) , a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • ACCESSWIRE6 months ago

    Sensus Healthcare to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that it will be presenting at the 8th Annual LD Micro Invitational on Tuesday, June 5 at 2:30pm PST/5:30pm EST. Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, will be presenting as well as meeting with investors. "The event is slated to be our largest Invitational to date," stated Chris Lahiji, President of LD Micro.